Evidence map›Paper›PMID 36388417›Full record

ArticleNeuro-oncology practice2022

Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting.

Rimas V Lukas, Steven J Chmura, Ian F Parney, Aaron Mammoser, Sonali M Smith, Jing Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rimas V LukasDepartment of Neurology, Northwestern University, Chicago, Illinois, USA.
Steven J ChmuraDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA.
Ian F ParneyDepartment of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
Aaron MammoserDepartment of Neurosurgery, Louisiana State University, New Orleans, Louisiana, USA.
Sonali M SmithDepartment of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois, USA.
Jing LiDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.

Funding

STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Atique U. Ahmed · 2018 to 2026
$21.4M
NCI NIH HHS P50 CA221747
6 · The paper itself

Abstract

In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.

Indexed as

brain metastasesglioblastomagliomaleptomeningeal metastasesmeeting reportneuro-oncology

Identifiers

PMID36388417
PMCPMC9665054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.